This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smirnov, D. A. Articles by O'Hara, S. M. Search for Related Content PubMed PubMed Citation Articles by Smirnov, D. A. Articles by O'Hara, S. M.

Global Gene Expression Profiling of Circulating Endothelial Cells in Patients with Metastatic Carcinomas

Immunicon Corp., Huntingdon Valley, Pennsylvania

Request for reprints: Leon Terstappen, Immunicon Corp., 3401 Masons Mill Road, Suite 100, Huntingdon Valley, PA 19006. Phone: 215-830-0777; Fax: 215-830-0751; E-mail: lterstappen{at}immunicon.com.

Increased numbers of endothelial cells are observed in peripheral blood of cancer patients. These circulating endothelial cells (CECs) may contribute to the formation of blood vessels in the tumor or reflect vascular damage caused by treatment or tumor growth. Characterization of these cells may aid in the understanding of the angiogenic process and may provide biomarkers for treatment efficacy of angiogenesis inhibitors. To identify markers typical for CECs in cancer patients, we assessed global gene expression profiles of CD146 immunomagnetically enriched CECs from healthy donors and patients with metastatic breast, colorectal, prostate, lung, and renal cancer. From the generated gene profiles, a list of 61 marker genes for CEC detection was generated, and their expression was measured by real-time quantitative PCR in blood samples from 81 metastatic cancer patients and 55 healthy donors that were immunomagnetically enriched for CECs. A set of 34 genes, among which novel CEC-associated genes, such as THBD, BST1, TIE1, POSTN1, SELE, SORT1, and DTR, were identified that were expressed at higher levels in cancer patients compared with healthy donors. Expression of the VWF, DTR, CDH5, TIE, and IGFBP7 genes were found to discriminate between cancer patients and "healthy" donors with a receiver operating characteristic curve accuracy of 0.93. Assessment of the expression of these genes may provide biomarkers to evaluate treatment efficacy. (Cancer Res 2006; 66(6): 2918-22)

This article has been cited by other articles:

				M. Cristofanilli and J. Mendelsohn Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy? PNAS, November 14, 2006; 103(46): 17073 - 17074. [Full Text] [PDF]